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Abstract
Background: Isoflurane in clinical use is a racemate of S- and R-isoflurane. Previous studies have demonstrated that the
effects of S-isoflurane on relevant anesthetic targets might be modestly stronger (less than 2-fold) than R-isoflurane. The X-
ray crystallographic structure of the immunological target, leukocyte function-associated antigen-1 (LFA-1) with racemic
isoflurane suggested that only S-isoflurane bound specifically to this protein. If so, the use of specific isoflurane enantiomers
may have advantage in the surgical settings where a wide range of inflammatory responses is expected to occur. Here, we
have further tested the hypothesis that isoflurane enantioselectivity is apparent in solution binding and functional studies.
Methods: First, binding of isoflurane enantiomers to LFA-1 was studied using 1-aminoanthracene (1-AMA) displacement
assays. The binding site of each enantiomer on LFA-1 was studied using the docking program GLIDE. Functional studies
employed the flow-cytometry based ICAM binding assay.
Results: Both enantiomers decreased 1-AMA fluorescence signal (at 520 nm), indicating that both competed with 1-AMA
and bound to the aL I domain. The docking simulation demonstrated that both enantiomers bound to the LFA-1 ‘‘lovastatin
site.’’ ICAM binding assays showed that S-isoflurane inhibited more potently than R-isoflurane, consistent with the result of
1-AMA competition assay.
Conclusions: In contrast with the x-ray crystallography, both enantiomers bound to and inhibited LFA-1. S-isoflurane
showed slight preference over R-isoflurane.
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Introduction
Many biologically active molecules, including drugs, exist in
different chiral forms, and it is possible that each specific
enantiomer can interact with their targets differently, thereby
potentially eliciting different biological responses. Thus, the
potential exists for a racemic mixture of a compound to cause
diverse, and perhaps unwanted, side effects. Regardless, racemic
drugs are used commonly in clinical medicine, as the purification
or synthesis of one specific enantiomer can be costly. Novel drug
discovery can be even more costly, so there has been recent
interest in exploiting enantioselectivity in the last two decades.
While the majority of drugs on the market were sold as racemic
mixtures in early 1990s, about 40% of drugs were marketed as
single enantiomers by 2002 [1]. Some of these single enantiomers
were newly developed, while some were isolated from the
previously marketed racemic mixtures [2]. The advantages of
using specific enantiomers over the racemic mixture might include
their less complex and more selective pharmacodynamic profiles,
and the potential for improved therapeutic index and the
reduction of side effects. In extreme cases, one enantiomer may
act as an antagonist (such as R(-)-PN 202-791; calcium channel
antagonist), while the other may be an agonist (such as S(+)-PN
202-791; calcium channel agonist) [3].
The interest in single enantiomers has also reached the
anesthesia field, as demonstrated by the introduction of ropiva-
caine and levo-bupivacaine [3]. Further, even the inhalational
general anesthetics have chiral centers. For example, isoflurane
has been successfully separated into its enantiomers by Huang et
al. and others in 1990s [4], allowing investigators to test the
potency of each separately. The S- enantiomer of isoflurane was
shown to be approximately 2-times more potent in vitro and in vivo
than R- enantiomer isoflurane (Table 1). However, the structural
basis for the differential potency of isoflurane enantiomers has yet
to emerge, but it has been reported that S-isoflurane binds with
higher affinity to model proteins, like human serum albumin [5].
Previously we demonstrated that isoflurane interacted with the
adhesion molecule leukocyte adhesion-associated antigen-1 (LFA-
1). This protein is expressed ubiquitously on leukocytes and is
involved in various immunological actions such as leukocyte arrest
on the endothelium [6] and immunological synapse formation [7].
This heterodimeric molecule consisting of a- and -b subunits is
PLOS ONE | www.plosone.org 1 May 2014 | Volume 9 | Issue 5 | e96649activated through the intracellular activation signals called the
‘‘inside-out’’ signal and undergoes dynamic conformational
changes [8,9]. The a7 helix of the ligand binding domain (the
aL I domain) of the a subunit is extremely flexible [10]. In a
resting (inactive) state, the a7 helix remains helical, forming a
pocket called the ‘‘lovastatin site.’’ In a high-affinity (active) state,
however, an unwinding, downward movement of the a7 helix
occurs causing a loss of the ‘‘lovastatin site’’, which allows the aLI
domain to bind ligands at the metal-ion dependent adhesion site
(MIDAS) (Figure 1). The X-ray crystallization of racemic
isoflurane complexed with the aL I domain demonstrated that
isoflurane bound to this ‘‘lovastatin site’’[11], and the functional
relevance of this binding in LFA-1 blockade by isoflurane was
shown by the mutagenesis experiment [12]. Interestingly, further
refinement of this complex suggested that only S-isoflurane, fit into
the electron density map of this region; the R-isomer produced a
steric clash with lining residues. This seemingly extreme example
of isoflurane stereoselectivity on LFA-1 suggested by the X-ray
crystallographic structure is striking as compared to the modest,
functional stereoselectivity suggested by its central nervous system
effects [13,14,15,16,17]. Our previous study demonsrated that the
interaction of racemic isoflurane with LFA-1 had functional
relevance in vivo [18]. Thus, if the suggested selectivity on LFA-1
can be demonstrated in solution, it may open the door to more
selective application of these drugs in the perioperative setting.
In this study, we tested the hypothesis that the enantioselectivity
of isoflurane suggested by the crystal structures of LFA-1-
isoflurane complex, is also observed in solution binding and
functional studies.
Methods
Protein expression and purification
The aL I domain wild type (WT, residues 128-307 of the
integrin aL subunit) (low affinity conformer) of LFA-1 were
expressed in BL21 (DE3) cells. The aI domains were expressed as
inclusion bodies, which were solubilized and refolded as previously
described [19]. Soluble full ectodomain LFA-1 protein was
expressed from CHO Lec 3.2.8.1 cells stably transfected with
LFA-1 plasmids and purified as previously described [20].
Cell-free LFA-1: ICAM-1 binding assays
LFA-1: ICAM-1 binding assays were performed as previously
described with minor modifications [21]. Briefly, soluble LFA-1
protein (10 mg/mL) was immobilized on the capturing antibody
named anti-Velcro antibody (Immune Disease Institute, Boston,
MA) on 96 well plates. Following blocking, human ICAM-1-Fca
fusion protein (5 mg/mL) was added to wells with HEPES-buffered
saline (HBS) containing 1 mM MnCl2 and in some cases, 10-
25 mM 1-aminoanthracene (1-AMA) (Sigma; St. Louis, MO,
USA). After incubation for 1 hour at room temperature, unbound
ICAM-1 was washed off and bound ICAM-1 was detected using
peroxidase-labeled goat anti-human IgA and substrate (BD,
Franklin Lakes, NJ, USA). Absorbance was measured at
405 nm. ICAM-1 binding % was defined as [(optimal density
(OD) of 1-AMA]/OD of mock-treated sample] 6100%.
Transient transfection of LFA-1 in 293 T cells
293 T cells were cultured in HEPES modified - Dulbecco’s
modified Eagle medium (DMEM)/10% fetal bovine serum (FBS)
at 37uC, 5% CO2. Wild type LFA-1 plasmid was transfected using
Lipofectamine 2000 (Invitrogen; Carlsbad, CA, USA).
Table 1. The previous studies using isoflurane enantiomers.
Type of experiment Study results Reference
In vivo The lipid emulsion of isoflurane injection to rats. S(+)w a s4 0 +/28% more potent than R(2) at producing
loss of righting reflex.
[35]
In vivo The inhalation of isoflurane enantiomers to rats. Minimum alveolar concentMAC was S(+); 1.06%, R(2);
1.62%, suggesting S(+) was about 50% more potent.
[36]
In vivo The determination of MAC using rats. Inhalational route. S(+): 0.0144 +/2 0.0012 atm, R(2);
0.0169 +/2 0.0020 atm. Not statistically significant.
[37]
In vivo Intraperitoneal injection of isoflurane enantiomers to mice. Sleep time was longer with S(+) over R(2). [38]
In vitro S(+) was more potent and efficacious than R(2) in enhancing [
3H] flunitrazepam binding to GABAA
receptor complex.
[13]
In vitro S(+) had greater increase in GABA receptor mediated IPSCs than R(2) [14]
In vitro S(+) was 1.6 times as potent as R(2) in augmenting GABA gated Cl flux. [15]
In vitro Cl flux induced by GABA was potentiated by isoflurane. The maximum stereoselectivity occurred at
0.3 mM isoflurane (S . R), about 2 times.
[16]
In vitro No stereospecific effects of isoflurane in isolated guinea pig hearts (the effect on LVP, AV conduction,
coronary flow)
[48]
In vitro No stereoselectivity of isoflurane seen to inhibit isradipine binding to L-type calcium channel [49]
In vitro S(+) bound bovine serum albumin with slower association and dissociation rates than R(2). No difference
in static condition.
[50]
In vitro S(+) was twofold more effective than R(2) both in eliciting the anesthetic-activated potassium current
and in inhibiting a current mediated by neuronal nicotinic acetylcholine receptors
[17]
The reported studies of isoflurane enantiomers are summarized in the table.
MAC; minimum alveolar concentration, GABA; gamma-aminobutyric acid, LVP; left ventricular pressure, AV; atrio-ventricular, IPSC; inhibitory postsynaptic current.
doi:10.1371/journal.pone.0096649.t001
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293 T cells were transiently transfected with LFA-1 on glass
bottom dishes (MatTek Corporation; Ashland, MA, USA). LFA-1
on the cells was stained with TS1/12 antibody (Immune Disease
Institute, Boston, MA, USA) followed by anti-mouse Cy5 antibody
(Life Technologies; Grand Island, NY, USA). 1-AMA was added
to medium, incubated for 10 minutes, and then the cells were
examined with fluorescence microscopy.
Chiral gas chromatography
Isoflurane enantiomers (S-isoflurane and R-isoflurane) were
kindly provided by Baxter (Cambridge, MA, USA). Racemic
isoflurane was from Abbott Laboratories (Abbott Park, IL, USA).
We first used chiral gas chromatography with mass spectrometry
detection (GC/MS) to evaluate the purity of each optical
enantiomer. Samples of isoflurane were diluted in heptane (Sigma)
and injected into the gas chromatography (Model G1540N-
6410N, Agilent Technologies; Santa Clara, CA, USA). We used a
30-m, 0.25-mm, 0.25 mm 20% permethylated b-cyclodextrin
chiral 20B column (Agilent Technologies). The parameters were
a split ratio of 1: 20, injector temperature of 70muC, oven
temperature of 60uC, and carrier gas hydrogen at 1 mL/min.
Mass spectrometry quantification was conducted in single ion
model at m/z 51, 117 and 141.
1-AMA competition assay
The competition of 1-AMA binding with the isoflurane
enantiomers was performed using the aL I domain. The aLI
domain (0.2 mM) was first pre-equilibrated with 10 mM 1-AMA
(Sigma; St. Louis, MO, USA). After addition of 0.1 mMt o4m M
of S-, or R- isoflurane, samples were excited at 380 nm and
emission spectra were collected from the range of 400 nm to
700 nm. The reduction of the fluorescence signal at 540 nm was
corrected by subtracting the baseline fluorescence curves of 1-
AMA and the aL I domain, and plotted against isoflurane
enantiomer concentration. Both competition curves were fitted to
variable slope Hill curves. Analysis was performed using PRISM 5
software (Graph Pad Software, La Jolla, CA, USA).
Docking simulation of S- and R-isoflurane
The structure of the aL I domain was obtained from the Protein
Data Bank (PDB) 1ZOO [22]. The program GLIDE (Schrodinger;
Cambridge, MA, USA) was used to perform rigid molecular
docking of isoflurane enantiomers with the aL I domain, as
previously described [20]. The structures of the isoflurane
enantiomers were obtained through PubChem (http://pubchem.
ncbi.nlm.nih.gov/). Isoflurane binding position was sought with
the grid size of 25 625 625 A ˚ 3 and the centroid grid residue of
Tyr-257. No positional constraint was applied. GLIDE has a
Figure 1. Schematic description of leukocyte function-associated antigen-1 (LFA-1) structure and ‘‘lovastatin site’’. Inactive and active
forms of LFA-1 are shown in cartoon. The a7 helix is very flexible as shown. In an inactive form, there is a cavity called ‘‘lovastatin site’’ underneath the
a7 helix of the aL I domain. There is no active signal communication from the bI domain to the aI domain. However, in an active form, the a7 helix of
the aI domain gets unwound and Glu-310, which has a negative charge, interacts with metal-ion dependent adhesion site (MIDAS) (positive charge)
in the bI domain. This is how the bI domain communicates with the aI domain. And MIDAS in the aI domain binds to the ligand.
doi:10.1371/journal.pone.0096649.g001
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predicted interaction free-energy. The pair with the most negative
glidescore is considered to have the highest affinity, thus we
selected the docked pair with the most negative glidescore.
Cell-based Intercellular adhesion molecule-1 (ICAM-1)
binding assay
ICAM-1 is the major endogenous ligand for LFA-1. A cell-
based LFA-1: ICAM-1 binding assay was performed using flow
cytometry as previously described [23]. Briefly, 293 T cells
transiently transfected with LFA-1 were harvested in HBS
containing 10 mM EDTA 48 hours after transfection. Cells were
washed with HBS, and then resuspended in HBS. Cells were
aliquoted to polymerase chain reaction tubes (Axygen; Union City,
CA, USA) and then centrifuged. Cell pellets were given150 ml
aliquot of HBS, 2 mM MnCl2 containing isoflurane at 2 6final
concentrations, and another 150 ml aliquot of HBS containing
10 mg/mL ICAM-1-Fca fusion protein. Tubes were immediately
capped, mixed, and incubated for 30 minutes at room tempera-
ture. Following wash, cells were incubated with anti-human IgA-
FITC (Invitrogen) as a secondary antibody for 30 minutes. The
cells were then washed and subjected to flow cytometry analysis
using a FACScan instrument (BD Bioscience; San Jose, CA, USA).
ICAM-1 binding % was defined as [mean fluorescence intensity
(MFI) of samples at various concentrations of isoflurane divided by
mean fluorescence intensity of mock-treated sample] 6100%.
Statistical analysis
All the statistical analyses were performed using PRISM 5
software. The details of statistical analysis were described in the
corresponding figure legends. P,0.05 was considered statistically
significant.
Results
The interaction of 1-AMA with LFA-1
1-AMA is a small molecule with environment-dependent
fluorescence and general anesthetic properties as demonstrated
by the potentiation of gamma-aminobutyric acid (GABA)-ergic
transmission [24,25,26]. It has been used to explore protein
cavities, and binds to a well-characterized ‘‘general anesthetic site’’
in horse spleen apoferritin (HSAF) [26,27]. We previously
Figure 2. The interaction of 1-aminoanthracene (1-AMA) with
leukocyte function-associated antigen-1 (LFA-1). (A) LFA-1:
ICAM-1 binding was tested in cell-free system in the presence of 1-
AMA. 1-AMA impaired ICAM-1 binding. (B) Localization of 1-AMA was
tested in transient LFA- 1 transfectants. In Figure, green represents 1-
AMA, and red represents LFA-1.
doi:10.1371/journal.pone.0096649.g002
Figure 3. The determination of isoflurane enantiomers’
binding to the aL I domain using 1-aminoanthracene (1-
AMA). (A) The reduction of fluorescence intensity versus isoflurane
concentration after displacement of 1-AMA from the aL I domain. Error
bars indicate standard deviation (S.D.) of means of three independent
experiments. (B) First, Kd values of S- and R-isoflurane in each
independent experiment was obtained. Then the average Kd values
of S- and R-isoflurane of three independet experiments were calculated
(S-isoflurane 374.8 mM, R-isoflurane 460.2 mM). Data represent mean +/-
S.D. F test was used for statistical analysis. No statistical significance was
observed (p=0.0629).
doi:10.1371/journal.pone.0096649.g003
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presence of aL I domain, suggesting that 1-AMA interacted with
LFA-1 [21]. Our previous direct photolabeling work showed that
propofol bound the ‘‘lovastatin site.’’ In addition propofol
displaced 1-AMA from LFA-1. We explored the size of available
cavities on the surface of aL I domain and found that only the
‘‘lovastatin site’’ was a larger cavity than 1-AMA. Thus we
concluded that 1-AMA bound the ‘‘lovastatin site.’’ This site is also
the binding site of LFA-1 allosteric antagonists, and therefore we
hypothesized that 1-AMA would block LFA-1. As shown in
Figure 4. The docking of isoflurane enatiomers at ‘‘lovastatin site’’. (A) The scheme of S- and R-isoflurane is shown. (B, C) The docking result
of isoflurane enatiomers onto the aL I domain is shown. Right panels showed blowup of the docking site. A part of amino acid residues within 4 s
3
from isoflurane were shown with side chains in green. In isoflurane: red, oxygen; green, chloride; light blue, fluoride.
doi:10.1371/journal.pone.0096649.g004
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ICAM-1.
The binding of 1-AMA to LFA-1 on the cell surface
The interaction of 1-AMA with LFA-1 was studied in a cell-
based system as well. Using microscopy, we asked if 1-AMA binds
to LFA-1 on the surface of transfected cells. 1-AMA fluorescence
was clearly co-localized with LFA-1 (Figure 2B), however, it was
also seen in non-transfected cells, indicating that it has other
binding targets. Because there are many proteins with hydropho-
bic cavities that can accommodate 1-AMA (,500 s
3)[28], this
was predicted. Our previous work showed that isoflurane bound
LFA-1 at the ‘‘lovastatin site’’ [12,20], so we hypothesized that
isoflurane and 1-AMA would compete at this site, with the S-
enantiomer being more potent than R-isoflurane. Because 1-AMA
displacement requires a small amount of reagents and the
available amount of isoflurane enantiomers is limited, we opted
to use this method in a cell-free system.
The purity of S- and R- isoflurane enantiomers
We validated that the S- and R-enantiomers as supplied by the
company were greater than 99% pure, and that the racemic
mixture consisted of 50% (62%) of each. (Figure S1A-C).
Interactions of the aL I domain with two isoflurane
enantiomers
Our hypothesis was that only S-isoflurane binds to the
‘‘lovastatin site’’. In contrast, however, both enantiomers reduced
fluorescence intensity, suggesting that they both interact with the
lovastatin site on the aL I domain (Figure 3A). The dissociation
constants (Kd) for S-isoflurane and R-isoflurane (374.8 mM and
460.2 mM, resp.) were not statistically different (Figure 3B).
Docking of S- and R-isoflurane into the aL I domain
Both enantiomers were successfully docked to the ‘‘lovastatin
site’’ using GLIDE (Figure 4B and 4C). The neighboring amino
acid residues are listed in Table 2. In both S-and R- isoflurane
docking models, the trifluoromethyl heads were in the same
orientation and formed hydrophobic interactions with Ile-235 and
Leu-302. However, the difluoromethyl groups assumed different
orientations. The difluoromethyl group in R-isoflurane had
hydrophobic interactions with Leu-298 and Leu-302, while in S-
isoflurane it interacted with Tyr-257 and Leu-302. Consistent with
the 1-AMA experiments, the comparison of the docking scores
indicated an inability to detect a significant difference of affinity to
the aL I domain between S- and R-isoflurane (Table 3).
Inhibition of LFA-1 by S- and R- isoflurane
The above results indicate that both isoflurane enantiomers
bind to the ‘‘lovastatin site,’’ although subtle differences may exist
which might be detectable using functional assays. Thus, we tested
if both enantiomers could inhibit ligand (ICAM) binding. We used
Mn
2+ to activate LFA-1, which mimics inside-out signaling as
described above. Also we confirmed that concentrations of S-, R-
and racemic isoflurane remained steady during the incubation for
30 minutes. Both S- and R-isoflurane inhibited the binding of
ICAM-1 to LFA-1 (Figure 5). Interestingly, S-isoflurane inhibited
ICAM-1 binding ,50% more potently than R-isoflurane,
indicating the presence of functional enantioselectivity of isoflur-
ane enantiomers to LFA-1.
Discussion
Here we have demonstrated that both S- and R-isoflurane
interact with LFA-1 at the lovastatin site, and impair its ligand
binding. 1-AMA displacement assay and docking simulations were
unable to detect a statistically significant difference in the
interaction of the aL I domain with isoflurane enantiomers. Both
enantiomers inhibited the binding of LFA-1 to ICAM-1 in cell-
Table 2. The distance of near-by amino acid residues from isoflurane (, 4A ˚).
Amino acid R-isoflurane (A ˚) S-isoflurane (A ˚)
Leu-132 3.0 3.2
Phe-134 3.9 3.6
Phe-153 3.4 2.8
Val-157 2.6 2.4
Ile-235 2.5 2.5
Tyr-257 3.9 2.9
Ile-259 3.5 3.6
Leu-198 2.8 3.5
Leu-302 2.4 2.4
Lys-305 3.8 3.9
doi:10.1371/journal.pone.0096649.t002
Table 3. GLIDE docking score.
S-isoflurane R-isoflurane
GLIDE score -4.495 -4.321
doi:10.1371/journal.pone.0096649.t003
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enantioselectivity of isoflurane on anesthetic targets in the CNS
has been documented as in Table 1, and in general indicate a
very modest effect. This study is the first to investigate the
enantioselectivity of targets relevant to immune function.
Our experimental results were inconsistent with structural
analysis of previous x-ray crystallography experiments, which
indicated that R-isoflurane could not bind this pocket due to steric
clash with Tyr-257 [11]. While X ray crystallography is a very
useful tool to provide detailed structural information, it may not
reflect subtle changes in protein dynamics that allow accommo-
dation of ligands (‘‘induced fit’’). Also, numerous lattice contacts at
the protein-protein interfaces can subtly alter the crystal structure
from the solution structure. Examples are alpha-lactalbumin [29],
myoglobin [30] and aspartate transcarbamylase [31]. Finally, it is
known that crystallization may not demonstrate structural
variability as in the case of intestinal fatty-acid-binding apoprotein
where X-ray crystallization did not demonstrate the variability of
backbone structure [32]. Both 1-AMA displacement and cell-
based ICAM-1 binding assays, were performed in a solution
setting where dynamics should be retained. The ‘‘lovastatin site’’
underneath the C-terminal a7-helix was demonstrated to be the
most variable region in reported I-domain X-ray crystallographic
structures [33], as demonstrated by the difference of cavity size
depending on the crystallization conditions [21]. The region was
quite flexible in solution nuclear magnetic resonance structures
[10]. Therefore, the probable explanation of the discrepancy
between the structural and our data is a loss of normal protein
flexibility or dynamics [10] that might normally result in ‘‘induced
fit’’, and which are reduced in the crystal due to multiple lattice
contacts, leading into the altered features of small molecule
binding sites. Our study further stresses the importance of solution-
based assay for the validation of crystallographic studies.
Pfeiffer’s rule states that the stereoselectivity of a drug is a
function of the mass of drug necessary to produce its pharmaco-
logical effects [34]. Given that isoflurane’s plasma concentration
that produces general anesthetic effects is relatively high (, mM
range), it is expected that isoflurane would demonstrate only
modest stereoselectivity. Accordingly, previous in vivo studies of
isoflurane enantiomers did not demonstrate more than a 20-50%
difference in anesthetic effect [35,36,37,38]. Our cell-based
functional results showed that a similar magnitude of functional
stereoselectivity was the case for LFA-1 as well. Previously, we
demonstrated that isoflurane also bound the top domain of the b2
subunit called the bI domain, which is also an important regulator
of ICAM-1 binding [20]. There could also be a difference of
affinity against this domain between S- and R- isoflurane, which
may explain the small difference of the results between 1-AMA
displacement assay (or docking simulation) using only the aLI
domain and cell-based ligand binding assay. Unfortunately, the
fact that the isolated b2 I domain protein has not been successfully
expressed [39] prevented us from testing this hypothesis.
LFA-1 antagonism by isoflurane has a few intriguing clinical
implications. For example, LFA-1 knockout mice had a higher
mortality than wild-type mice after intraperitoneal S. pneumoniae
infection [40]. However, Emoto et al. demonstrated that LFA-1
knockout mice were resistant to lipopolysaccharide-induced liver
injury [41]. Further, Miyamoto et al. showed that LFA-1 knockout
mice had resistance to Listeria monocytogenes infection [42].
Blockade of LFA-1 has been shown to be beneficial in graft
survival in various transplantation models [43,44,45]. A clinical
pilot study of allo-islet transplantation recipients treated with the
humanized anti-LFA-1 antibody efalizumab showed a favorable
outcome [46]. In addition, efalizumab has been used to treat
psoriasis [47]. Unfortunately, this drug has been withdrawn from
the market due to a risk of fatal brain infections. These studies
demonstrate that LFA-1 blockade could be beneficial or
detrimental depending on circumstances. Also it has to be noted
that many of these studies have been done with permanent LFA-1
blockade (knockout mice), or antibody blockade which usually has
a prolonged effect. In our previous studies, we demonstrated that a
short exposure of isoflurane (2–4 hours) attenuated neutrophil
recruitment in the setting of skin inflammation, a process in which
LFA-1 plays a large role. In the future, the impact of transient
LFA-1 blockade by anesthetics needs to be examined. The answer
to this question will allow us to consider to redesigning, or
reformulating our anesthetic drugs to mitigate this LFA-1
functional alteration.
Additional finding in this study is that 1-AMA, which is a
general anesthetic binding site probe, possessing general anesthetic
activity, is an LFA-1 antagonist and bound LFA-1 on the cell
Figure 5. The ligand binding assay of leukocyte function-associated antigen-1 (LFA-1) using isoflurane enantiomers. The binding of
LFA-1 to ICAM-1 in the presence of isoflurane (racemate, enantiomers) was tested using 293T cells overexpressing LFA-1 using flow cytometry as
described in the method. Data represent mean +/- S.D. of triplicates. To compare any difference in ICAM-1 binding % in the presence of racemic, S-
and R- isoflurane, statistical analysis was performed using two-way ANOVA with Bonferroni post hoc analysis. * denotes p,0.05.
doi:10.1371/journal.pone.0096649.g005
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clouds interpretation.
In conclusion, we have demonstrated that both isoflurane
enantiomers interact with LFA-1, an important component of
immunologic cascades, with evidence for subtle enantioselectivity.
The clinical significance of this interaction remains to be
determined in the future.
Supporting Information
Figure S1 Chiral gas chromatography of isoflurane. The
gas chromatographic traces were shown. (A) racemic isoflurane,
(B) S- or (C) R- isoflurane. The area under the curve was used to
calculate the composition of S- and R-isoflurane in each solution.
X-axis represents retention time (min), and y-axis represents
detector (arbitrary unit).
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